With the Helmholtz Validation Fund, the Helmholtz Association supports projects that are particularly promising in translating research findings into viable commercial applications. Among the seven projects chosen for funding this year is a project from the MDC.
Transferring MDC inventions into pharmaceuticals and therapies – this is the mission driving MDC’s department of technology transfer. Their latest achievement, a pharmaceutical substance for atrial fibrillation developed by MDC spin-off OMEICOS Therapeutics, is now entering clinical trials.
Researchers at the MDC have developed antibodies that promise to heal multiple myeloma. The biotechnology company Heidelberg Pharma will now develop one of these antibodies to an antibody-toxin agent and test it clinically at the end of 2018.
A big moment for cancer-fighting T-cell therapy: “Captain T Cell,” a start-up project led by researchers from the MDC, has won this year’s OneStart competition in London.
Researchers at the MDC want to translate a new cancer therapy involving reprogrammed immune cells from the laboratory scale to the clinic, and are cooperating with industry partners to achieve this. The Helmholtz Association is supporting the transfer process by setting up a Helmholtz Innovation Lab at the MDC.
“VONVENDI [von Willebrand factor (Recombinant)]”, the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration. It is the first, and so far the only, recombinant protein for the treatment of von Willebrand disease, and offers those affected […]
The drug Blincyto (Blinatumomab) has now been approved by the European Medicines Agency. Blinatumomab is used to treat patients with a very aggressive form of blood cancer, and is the result of work carried out at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) over ten years ago. Start-up company Micromet […]
We are pleased to announce Ulrich Gohlke and his team as the winner of the “MDC Young Science Transfer Award” for his technology transfer project. The prize is endowed with € 15,000. Dr. Gohlke belongs to the research group of Udo Heinemann and works on the development of substances to treat prostate cancer. He […]
In scientific research the discovery of a new type of molecule that regulates the flow of information from genes to proteins has a big impact. Such new regulators are top candidates to tackle human diseases at their roots as they govern on one of the most fine-tuned cellular processes. Today’s rapid development in technology enables […]